Gamma-secretase modulation and its promise for Alzheimer's disease: a rationale for drug discovery.
The genetics of Alzheimer's disease (AD) implies that restoring non-pathological levels or ratios of different amyloid-beta (Abeta) peptide species in the brain could prevent the onset or delay the progression of this neurodegenerative disease. In particular, a selective reduction of the longer Abeta(1-42) peptide which is widely believed to be causative of AD is currently seen as an attractive approach for a disease-modifying therapy. Based on the knowledge that Abeta(1-42) and various shorter Abeta peptides are generated by the same gamma secretase enzyme, the concept of allosteric modulation of the cleavage specificity of this aspartic protease has been introduced to the field of protease drug discovery and fuelled novel medicinal chemistry efforts. Gamma-secretase modulation holds the promise that chemical entities can be synthesized which restore non-pathological enzyme activity by shifting the actual substrate cleavage towards the generation of shorter Abeta peptides. It can be assumed that this approach has gained considerable attraction for pharmaceutical drug discovery since the development of non-selective protease inhibitors for gamma-secretase has been proven to be difficult due to inherent mechanism-based liabilities.
Beher
Dirk
D
Amgen Inc., Department of Neuroscience, One Amgen Center Drive, Thousand Oaks, CA 91320, USA. dbeher@amgen.com
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000627:therapeutic use*; D006801:Humans
D004791:Enzyme Inhibitors; D053829:Amyloid Precursor Protein Secretases